**Name of Journal: *World Journal of Hepatology***

**ESPS Manuscript NO: 22709**

**Manuscript Type: META-ANALYSIS**

**Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: A meta-analysis**

Stine JG *et al*.Portal vein thrombosis increases patient mortality

**Jonathan G Stine, Puja M Shah, Scott L Cornella, Sean R Rudnick, Marwan S Ghabril, George J Stukenborg, Patrick G Northup**

**Jonathan G Stine, Sean R Rudnick, Patrick G Northup,** Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, VA 22908, United States

**Puja M Shah,** Department of Surgery, University of Virginia, Charlottesville, VA 22908, United States

**Scott L Cornella,** Department of Medicine, University of Virginia, Charlottesville, VA 22908, United States

**Marwan S Ghabril,** Division of Gastroenterology and Hepatology, Indiana University, Indianapolis, IN 46202, United States

**George J Stukenborg,** Department of Public Health Science, University of Virginia, Charlottesville, VA 22908, United States

**Author contributions:** Stine JG and Shah PM contributed equally to this work; Stine JG, Shah PM, Ghabril MS, Stukenborg GS and Northup PG designed research; Stine JG, Shah PS, Cornella SL, and Rudnick SR performed research; Stine JG and Shah PM analyzed data, Stine JG, Shah PM, Cornella SL, Rudnick SR, Ghabril MS, Stukenborg GS and Northup PG wrote the paper.

**Supported by** (In part) grant funding from the National Institutes of Health (Grant 5T32DK007769-15); and NIH-Surgical Oncology grant (T32 CA163177).

**Conflicts of interest** **statement:** We have no conflicts of interest to report.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to: Jonathan G Stine, MD, MSc,** Division of Gastroenterology and Hepatology,University of Virginia,JPA and Lee Street, MSB 2145, PO Box 800708,Charlottesville, VA 22908-0708, United States. [jgs9f@virginia.edu](mailto:jgs9f@virginia.edu)

**Telephone**: +1-434-9242959

**Fax:** +1-434-2447529

**Received:** September 18, 2015

**Peer-review started:** September 19, 2015

**First decision:** October 21, 2015

**Revised:** November 2, 2015

**Accepted:** November 10, 2015

**Article in press:**

**Published online:**

**Abstract**

**AIM:** To determine the clinical impact of portal vein thrombosis in terms of both mortality and hepatic decompensations (variceal hemorrhage, ascites, portosystemic encephalopathy) in adult patients with cirrhosis.

**METHODS:** We identified original articles reported through February 2015 in MEDLINE, Scopus, Science Citation Index, AMED, the Cochrane Library, and relevant examples available in the grey literature. Two independent reviewers screened all citations for inclusion criteria and extracted summary data. Random effects odds ratios were calculated to obtain aggregate estimates of effect size across included studies, with 95% confidence intervals.

**RESULTS:** A total of 226 citations were identified and reviewed, and 3 studies with 2,436 participants were included in the meta-analysis of summary effect. Patients with portal vein thrombosis had an increased risk of mortality (OR = 1.62, 95%CI: 1.11-2.36, *P*=0.01). Portal vein thrombosis was associated with an increased risk of ascites (OR = 2.52, 95%CI: 1.63-3.89, *P* < 0.001). There was insufficient data available to determine the pooled effect on other markers of decompensation including gastroesophageal variceal bleeding or hepatic encephalopathy.

**CONCLUSION:** Portal vein thrombosis appears to increase mortality and ascites, however, the relatively small number of included studies limits more generalizable conclusions. More trials with a direct comparison group are needed.

**Key words:** Hepatology; Coagulopathy; Liver; Ascites; Hepatic encephalopathy; Portal hypertension

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Portal vein thrombosis (PVT) is a common complication of cirrhosis with resultant downstream hepatic decompensation and mortality. Treatment options carry risk and are not without complications. To date, there is a lack of systematic evidence on the clinical importance of PVT. We performed a systematic review and meta-analysis to determine the aggregate estimates of effect of PVT on hepatic decompensation and mortality. PVT appears to significantly increase mortality (OR = 1.62, 95%CI: 1.11-2.36) and ascites (OR = 2.52, 95%CI: 1.63-3.89), however, the small number of included studies limits more generalizable conclusions. More trials with a direct comparison group are needed.

Stine JG, Shah PM, Cornella SL, Rudnick SR, Ghabril MS, Stukenborg GJ, Northup PG. Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: A meta-analysis. *World J Hepatol* 2015; In press

**INTRODUCTION**

Portal vein thrombosis (PVT) is defined as an obstruction of the portal vein or its branches, which include the splenic, superior mesenteric, and inferior mesenteric veins[1]. It is associated with numerous conditions including malignancy, myeloproliferative disorders, inflammatory conditions (such as pancreatitis), intra-abdominal infections (such as secondary peritonitis), and cirrhosis[2,3]. PVT is common in patients with cirrhosis; over 30% of liver transplant recipients have PVT on direct explant examination at the time of transplant (LT) [2,4,5]. Incidence rates of PVT while variable, are reported to be as high as 16%[6]. The mechanism of PVT development in cirrhosis is multifactorial and is due to a combination of changes in liver architecture leading to impaired blood flow and endothelial cell activation, hypercoagulability, and the potential development of hepatocellular carcinoma (HCC)[7].The presence of PVT appears to be associated with the severity of underlying liver disease and hepatic decompensation from a mechanistic standpoint. However, the field of coagulation disorders and chronic liver disease is ever evolving and continues to generate controversy, in particular, when consideration is given to the impact of PVT on the development of hepatic decompensation. Multiple studies have been published indicating adverse clinical outcomes in the setting of PVT in both transplant and non-transplant populations, including hepatic decompensation, increased post-transplant mortality, and decreased quality of life[7-10]. Others have argued that PVT does not affect clinically relevant outcomes[11]. Due to this uncertainty, we sought to determine the clinical impact of PVT on transplant free survival and hepatic decompensation in adult patients with cirrhosis.

**MATERIALS AND METHODS**

***Literature search strategy and study selection***

The investigators systematically searched the published medical literature for observational studies and clinical trials that compared mortality or hepatic decompensation outcomes in cirrhosis patients with and without PVT. Published studies were identified by searching the following electronic databases: MEDLINE, Scopus, Science Citation Index, AMED, and the Cochrane Library. The search criteria included all publications through February 2015 with English language restriction. Electronic search criteria included the following terms or keywords: “portal vein thrombosis,” “mesenteric thrombosis,” "splanchnic thrombosis," "cirrhosis," "mortality," "decompensation," and "humans." We reviewed the reference lists of included articles in order to identify articles missed in the database searches. Recent conference abstract lists and other relevant grey literature sources were also searched for examples of relevant studies using the same terms and keywords. Studies were excluded if PVT was associated with only malignancy, developed post-procedure (surgery or interventional), were found in non-cirrhotic patients with portal hypertension, were in LT-only recipients, if no control/comparison group without PVT was included, or if survival was not analyzed. This study did not require institutional review board approval.

***Data extraction***

Two study personnel (Stine JG and Shah PM) independently screened the abstracts and titles of all studies identified using the electronic and manual search criteria to identify studies meeting the inclusion criteria. Each study meeting requirements of the first-round inclusion criteria then underwent a full-text independent review by both reviewers. Disagreements about inclusion between reviewers were resolved by follow-up consultation, and if necessary by a third clinical reviewer (Cornella CL). Two reviewers independently extracted the following data from each study that met inclusion criteria: patient characteristics (age, gender, MELD, and etiology of liver disease), study-level characteristics (author, publication year, study design, enrollment period, target population, total number of enrolled patents, and percentage of patients with PVT) and outcomes (mortality and hepatic decompensation).

***Primary and secondary outcomes***

Mortality was the primary outcome assessed. Secondary outcomes included the presence of or development of new gastroesophageal variceal bleeding, ascites, hepatic encephalopathy, and an aggregate measure of the occurrence of any of these three hepatic decompensation outcomes.

***Study quality and risk of bias assessment***

The quality of observational studies was assessed using the methods described by Stroup *et al*[12]. Only studies deemed high-quality by the investigators were included in the analysis. The Newcastle-Ottowa Quality Assessment for Cohort Studies scale[13] was used to further characterize the quality of studies based on selection of study groups, comparability of groups, and ascertainment of outcome. The studies are rated on an 8-point scale separated by the three broad sections delineated above.

### *Statistical analysis*

### Descriptive analysis of the studies identified, excluded, and included, and meta-analysis of the reported study effect measures, was conducted utilizing review manager software (Rev-Man version 5.3; Copenhagen; The Nordic Cochrane Centre; The Cochrane Collaboration; 2014). We estimated pooled odds ratios (ORs) and calculated corresponding 95%CIs using DerSimonian and Laird random-effects models, which account for both between and within study variability given that the included studies were not functionally identical[14,15]. Between study variability was separately assessed using the Cochran’s Q statistic (with *P* < 0.05 considered significant). The proportion of heterogeneity accounted for by between-study variability was estimated using the *I2* index and adjudicated to be significant if *I2* was > 75%[14,15]. A post-hoc funnel plot was created to assess for the presence or absence of publication bias.

**RESULTS**

***Included studies***

The electronic search criteria identified 226 studies. After ensuring no duplicates were present, we screened titles and abstracts. The full text of eleven studies was assessed for eligibility. Following the qualitative systematic review process, three observational studies met the inclusion criteria for the current meta-analysis[7,16,17]. Of these, two were retrospective[7,17]. The third study followed a prospective cohort of patients[16]. No additional studies were appropriate for inclusion based on our a-priori determined inclusion and exclusion criteria. Nery *et al*[11] recently published a multicenter prospective series of 1243 adult patients with cirrhosis without baseline PVT in France and Belgium. About 118 patients developed *denovo* PVT during a median follow-up period of 47 mo. This study, while initially considered in full-text review, was excluded specifically because absolute numbers for mortality or individual types of hepatic decompensation were not provided; rather, univariate and multivariable analysis *P-*values were provided only and only a composite of hepatic decompensation was given in absolute number.

The 3 eligible reports evaluated cirrhotic patients that did not initially have PVT, but developed it sometime over the study period. They each excluded patients with HCC and prior transplant. All 3 studies evaluated long-term outcomes in cirrhotic patients with PVT compared to cirrhotic patients without PVT. Study level characteristics are found in Table 1. A summary of the search results is presented in Figure 1, reflecting the reporting standards of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses [18].

The Englesbe *et al*[7] study assessed a total of 3295 (148 with PVT and 3147 without PVT) cirrhotic patients between 1995-2007. The study assessed patients that were being evaluated as candidates for liver transplantation that had thrombus in the main portal vein only. Patients with partial thrombus or thrombi in portal vein branches, without extension into the main portal vein were excluded. The Maruyama *et al*[17] article evaluated a total of 150 patients with viral hepatitis, 42 had PVT ( and 108 did not have PVT). The study by John *et al*[16] found 290 patients with cirrhosis, 70 of these had PVT and 220 did not. Notably, both the Maruyama *et al*[17] and John *et al*[16] articles specified patients with complete and partial thrombus, unlike the Englesbe study[7].

In total, the three studies included 3735 cirrhotic patients, 260 of which had PVT. Lengths of follow-up ranged from less than one month to 136 mo, with mean follow-ups ranging from 25 mo to 50 mo. Baseline demographic characteristics were similar between PVT and non-PVT groups in all 3 studies. There were no differences in regards to race, age, gender, causes of cirrhosis, or model for end stage liver disease (MELD) scores. Demographic and etiologic characteristics of the patients included in each studies are summarized in Table 2.

***Bias assessment***

All 3 studies include cohorts drawn from their abdominal transplant clinic population. The patients were truly representative of the average transplant population. Exposed and unexposed patients (patients with cirrhosis with spontaneous PVT and those without PVT) were all drawn from their transplant clinic population and all information was obtained through medical records in the three studies. The Englesbe *et al*[7] study controlled for PVT along with MELD, age, and presence of hepatitis C virus in a multivariable logistic regression with survival as the outcome. The Maruyama *et al*[17]study does not include a model controlling for covariates. The John *et al*[16] study does control for ascites and renal function, however this study created a multivariable model to identify predictors for PVT development. All three studies had widely variable amounts of follow-up and there is no information available on patients lost to follow-up for any of the studies. Based on these characteristics, the Englesbe *et al*[7] study received a score of 7/8, while Maruyama *et al*[17] and John *et al* [16] both received 6/8. The potential for publication bias was assessed using a funnel plot of the relationship between reported effect variance (SE(log[OR]) and the reported study OR. The plot illustrates the lack of evidence for potential publication bias in the three studies—the study with the largest effect size is the largest study included while the smaller studies have lower effect sizes (Figure 3).

***Portal vein thrombosis and mortality***

The Englesbe *et al*[7] article demonstrated an incidence rate of 4.5% for PVT. The patients with PVT were at significantly higher risk of mortality with an OR of 2.04 (95% CI 1.46-2.84) (Figure 2) Conversely, the Maruyama *et al*[17] and John *et al*[16] studies found higher rates of mortality between PVT and non-PVT subjects. The OR for mortality for PVT in both studies were 1.13 and 1.27, respectively but these differences were non-significant. Pooled analysis of the results reported across all 3 studies demonstrates a significantly increased risk of mortality in PVT patients (OR = 1.62, 95%CI: 1.11-2.36, *P* = 0.01). The Cochran’s Q statistic was non-significant at *P*=0.23 and *I2*=32%, demonstrating non-significant heterogeneity of effects reported across studies.

***Portal vein thrombosis and hepatic decompensation***

Secondary outcomes included episodes of hepatic decompensation, including individual cases of ascites, variceal bleeding, or portosystemic encephalopathy. Both John *et al*[16] and Maruyama *et al*[17] demonstrated similar effects of PVT on ascites development. John *et a*[16] showed an OR of 1.51 (95%CI: 0.87-2.60) compared to an OR of 7.46 (95%CI: 3.38-16.45) in the Maruyama *et al*[17] study (Figure 4). The Englesbe *et al*[7] study was excluded from this portion of analysis since they did not report on rates of hepatic decompensation. When the pooled OR was evaluated using random-effects modeling, PVT continued to have statistically significant higher odds of hepatic decompensation (OR = 2.52, 95% CI: 1.63-3.89, *P* < 0.001). The Cochran’s Q statistic and I2 were both significant for heterogeneity in this analysis. There was insufficient data available to determine the pooled effect on other markers of decompensation including gastroesophageal variceal bleeding or hepatic encephalopathy.

**DISCUSSION**

Our systematic review and meta-analysis is the first study to offer a pooled estimate and quantitative assessment of the clinical impact of PVT in terms of both mortality and hepatic decompensation. We have demonstrated a significantly increased rate of mortality for patients with cirrhosis and PVT when compared to those patients without PVT. This finding is important because PVT is a common finding in patients with cirrhosis[4,6,19] and one that significantly impairs quality of life and post-LT outcomes[7-9]. Several risk factors have been suggested to increase the risk of PVT in patients awaiting liver transplantation, including non-alcoholic steatohepatitis[20].

The risk of hepatic decompensation with ascites for patients with cirrhosis was also significantly greater in the presence of PVT. Evaluating a pooled estimate of risk for gastroesophageal variceal hemorrhage or ascites resulting from PVT could not be performed due to the lack of data reporting by the included studies. While this has been shown in other studies, these were not included due to a lack of a comparison group.

PVT appears to increase mortality and hepatic decompensation (composite as well as variceal hemorrhage and ascites), however, the relatively small number of included studies limits generalizable conclusions. Our study has several other limitations. Multiple studies with a large number of patients were excluded due to a lack of a comparison group, and our literature search revealed a general lack of randomized controlled trials within the context of PVT. The large multicenter prospective study by *Nery et al*[11] was specifically excluded due to a lack of absolute numbers and component hepatic decompensation assessment. The inclusion of only three studies also limits the systematic assessment for publication bias and may also have resulted in the large degree of heterogeneity seen in calculation of the pooled measure of effect for PVT and the development of ascites.

Regardless, this current review represents the best available summary of the evidence to date and highlights a significant need for future research around the implications of PVT, especially prospective studies with a direct comparator group. Safety and efficacy data on both prevention and treatment of PVT is in general lacking. Villa *et al*[21] recently published their unblinded randomized, single center experience having found that daily prophylactic dosing of low molecular weight heparin (the equivalent of 40 mg/d) for twelve months prevented the development of PVT in patients with compensated cirrhosis. While the study was terminated at 48 wk, the effect persisted through follow-up at 5 years when compared to standard of care[21]. Additionally, the authors demonstrated less hepatic decompensation in the low molecular weight heparin arm (*P* < 0.0001) and a more importantly, a significant survival benefit[21]. Building on this work, Cui *et al*[22] published their single center randomized trial of 65 patients investigating therapeutic doses of low-molecular weight heparin (1 mg/kg every twelve hours or 1.5 mg/kg daily), where 78.5% (*n* = 51) responded to treatment with either complete or partial recanalization at 6 mo after starting therapy. These responders had regression of their liver disease when compared directly to the 14 non-responders. Similar to Villa *et al*[21], Cui *et al*[22] found no episodes of variceal hemorrhage, however, they did find much higher rates of non-variceal bleeding (6.4%-23.5%). While this study has several limitations including its generalizability as it only enrolled hepatitis B patients in China, it is nonetheless promising. With the development of new oral anticoagulants, the promise of treatment and possibly prevention is becoming a reality23]. More rigorous study is needed in the field of coagulation disorders in a randomized, placebo controlled interventional or preventative trial with a direct comparator group using either heparin based or new direct acting oral anticoagulant therapy.

In conclusion, PVT appears to increase mortality and hepatic decompensation from ascites, however, the relatively small number of included studies limits generalizable conclusions and contributes significant heterogeneity in the pooled measures of effect. More prospective, randomized placebo controlled trials with a direct comparator group are needed.

**COMMENTS**

***Background***

Non-neoplastic portal vein thrombosis is a common complication of cirrhosis. Treatment options carry risk and are not without complications. To make appropriate clinical decisions, clinicians need to be cognizant of the available evidence.

***Research frontiers***

The field of coagulation disorders in chronic liver disease is ever expanding. Much of the research focuses on portal vein thrombosis and clinically relevant outcomes with the goal of preventing hepatic decompensation through either prevention or treatment of portal vein thrombosis.

***Innovations and breakthroughs***

In the present study, the authors investigated the impact of portal vein thrombosis on mortality and hepatic decompensation in patients with cirrhosis. This is the first report of a meta-analysis in patients with cirrhosis specifically excluding those who go on to receive liver transplantation.

***Applications***

The present report furthers understanding regarding the clinical importance of portal vein thrombosis in patients with underlying cirrhosis.

***Peer-review***

This systematic review and meta-analysis adds useful information for both clinical practice and further academic research with the goal of impacting patient centered outcomes.

**REFERENCES**

1 **Kinjo N**, Kawanaka H, Akahoshi T, Matsumoto Y, Kamori M, Nagao Y, Hashimoto N, Uehara H, Tomikawa M, Shirabe K, Maehara Y. Portal vein thrombosis in liver cirrhosis. *World J Hepatol* 2014; **6**: 64-71 [PMID: 24575165 DOI: 10.4254/wjh.v6.i2.64]

2 **DeLeve LD**, Valla DC, Garcia-Tsao G. Vascular disorders of the liver. *Hepatology* 2009; **49**: 1729-1764 [PMID: 19399912 DOI: 10.1002/hep.22772]

3 **Ogren M**, Bergqvist D, Björck M, Acosta S, Eriksson H, Sternby NH. Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. *World J Gastroenterol* 2006; **12**: 2115-2119 [PMID: 16610067]

4 **Wanless IR**, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. *Hepatology* 1995; **21**: 1238-1247 [PMID: 7737629]

5 **Okuda K**, Ohnishi K, Kimura K, Matsutani S, Sumida M, Goto N, Musha H, Takashi M, Suzuki N, Shinagawa T. Incidence of portal vein thrombosis in liver cirrhosis. An angiographic study in 708 patients. *Gastroenterology* 1985; **89**: 279-286 [PMID: 4007419]

6 **Zocco MA**, Di Stasio E, De Cristofaro R, Novi M, Ainora ME, Ponziani F, Riccardi L, Lancellotti S, Santoliquido A, Flore R, Pompili M, Rapaccini GL, Tondi P, Gasbarrini GB, Landolfi R, Gasbarrini A. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. *J Hepatol* 2009; **51**: 682-689 [PMID: 19464747 DOI: 10.1016/j.jhep.2009.03.013]

7 **Englesbe MJ**, Kubus J, Muhammad W, Sonnenday CJ, Welling T, Punch JD, Lynch RJ, Marrero JA, Pelletier SJ. Portal vein thrombosis and survival in patients with cirrhosis. *Liver Transpl* 2010; **16**: 83-90 [PMID: 20035521 DOI: 10.1002/lt.21941]

8 **Rodríguez-Castro KI**, Porte RJ, Nadal E, Germani G, Burra P, Senzolo M. Management of nonneoplastic portal vein thrombosis in the setting of liver transplantation: a systematic review. *Transplantation* 2012; **94**: 1145-1153 [PMID: 23128996 DOI: 10.1097/TP.0b013e31826e8e53]

9 **Hibi T**, Nishida S, Levi DM, Selvaggi G, Tekin A, Fan J, Ruiz P, Tzakis AG. When and why portal vein thrombosis matters in liver transplantation: a critical audit of 174 cases. *Ann Surg* 2014; **259**: 760-766 [PMID: 24299686 DOI: 10.1097/SLA.0000000000000252]

10 **Ponziani FR**, Zocco MA, Senzolo M, Pompili M, Gasbarrini A, Avolio AW. Portal vein thrombosis and liver transplantation: implications for waiting list period, surgical approach, early and late follow-up. *Transplant Rev (Orlando)* 2014; **28**: 92-101 [PMID: 24582320 DOI: 10.1016/j.trre.2014.01.003]

11 **Nery F**, Chevret S, Condat B, de Raucourt E, Boudaoud L, Rautou PE, Plessier A, Roulot D, Chaffaut C, Bourcier V, Trinchet JC, Valla DC. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. *Hepatology* 2015; **61**: 660-667 [PMID: 25284616 DOI: 10.1002/hep.27546]

12 **Stroup DF**, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA* 2000; **283**: 2008-2012 [PMID: 10789670]

13 **Stang A**. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol* 2010; **25**: 603-605 [PMID: 20652370 DOI: 610.1007/s10654-10010-19491-z]

14 **Haidich AB**. Meta-analysis in medical research. *Hippokratia* 2010; **14**: 29-37 [PMID: 21487488]

15 **Murad MH**, Montori VM, Ioannidis JP, Jaeschke R, Devereaux PJ, Prasad K, Neumann I, Carrasco-Labra A, Agoritsas T, Hatala R, Meade MO, Wyer P, Cook DJ, Guyatt G. How to read a systematic review and meta-analysis and apply the results to patient care: users' guides to the medical literature. *JAMA* 2014; **312**: 171-179 [PMID: 25005654 DOI: 110.1001/jama.2014.5559]

16 **John BV**, Konjeti R, Aggarwal A, Lopez R, Atreja A, Miller C, Zein NN, Carey WD. Impact of untreated portal vein thrombosis on pre and post liver transplant outcomes in cirrhosis. *Ann Hepatol* 2013; **12**: 952-958 [PMID: 24114826]

17 **Maruyama H**, Okugawa H, Takahashi M, Yokosuka O. De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes. *Am J Gastroenterol* 2013; **108**: 568-574 [PMID: 23381015 DOI: 10.1038/ajg.2012.452]

18 **Hutton B**, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. *Ann Intern Med* 2015; **162**: 777-784 [PMID: 26030634 DOI: 710.7326/M7314-2385]

19 **Gayowski TJ**, Marino IR, Doyle HR, Echeverri L, Mieles L, Todo S, Wagener M, Singh N, Yu VL, Fung JJ, Starzl TE. A high incidence of native portal vein thrombosis in veterans undergoing liver transplantation. *J Surg Res* 1996; **60**: 333-338 [PMID: 8598664 DOI: 10.1006/jsre.1996.0053]


20 **Stine JG**, Shah NL, Argo CK, Pelletier SJ, Caldwell SH, Northup PG. Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis. *Liver Transpl* 2015; **21**: 1016-1021 [PMID: 25845711 DOI: 10.1002/lt.24134]

21 **Villa E**, Camma C, Marietta M, Luongo M, Critelli R, Colopi S, Tata C, Zecchini R, Gitto S, Petta S, Lei B, Bernabucci V, Vukotic R, De Maria N, Schepis F, Karampatou A, Caporali C, Simoni L, Del Buono M, Zambotto B, Turola E, Fornaciari G, Schianchi S, Ferrari A, Valla D. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. *Gastroenterology* 2012; **143**: 1253-1260.e1-4 [PMID: 22819864 DOI: 10.1053/j.gastro.2012.07.018]


22 **Cui SB**, Shu RH, Yan SP, Wu H, Chen Y, Wang L, Zhu Q. Efficacy and safety of anticoagulation therapy with different doses of enoxaparin for portal vein thrombosis in cirrhotic patients with hepatitis B. *Eur J Gastroenterol Hepatol* 2015; **27**: 914-919 [PMID: 25856686 DOI: 10.1097/meg.0000000000000351]

23 **Intagliata NM**, Maitland H, Northup PG, Caldwell SH. Treating thrombosis in cirrhosis patients with new oral agents: ready or not? *Hepatology* 2015; **61**: 738-739 [PMID: 24829112 DOI: 10.1002/hep.27225]


**P-Reviewer:** Liang Y, Lim EC, Wang SK **S-Editor:** Wang JL **L-Editor: E-Editor:**



**Figure 1 The Preferred Reporting Items for Systematic Reviews and Meta-Analyses diagram.** About226 records were screened in aggregate; 11 full text articles were reviewed; 3 studies met inclusion criteria.



**Figure 2 Portal vein thrombosis and mortality.** PVT is associated with an increased pooled risk of death in the absence of significant heterogeneity.



**Figure 3 Funnel plot assessing publication bias.** No significant publication bias was observed in this study.

****

**Figure 4 Portal vein thrombosis and ascites.** PVT is associated with an increased pooled risk of hepatic decompensation manifested as ascites. This conclusion may be limited by heterogeneity in the included studies.

**Table 1 Study level characteristics *n* (%)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Author** | **Date Published** | **Dates enrolled** | **Enrollment** | **PVT** | **Death- no PVT** | **Death- PVT** |
| John *et al*[16] | 2013 | 2004-2009 | 290 | 70 (24.1) | 62 (28.2) | 24 (34.3) |
| Maruyama *et al*[17] | 2013 | 1998-2009 | 150 | 42 (28.0) | 21 (19.4) | 9 (21.4) |
| Englesbe *et al*[7] | 2010 | 1995-2007 | 3295 | 148 (4.5) | 1171 (37.2) | 81 (54.7) |

PVT: Portal vein thrombosis.

**Table 2 Patient level characteristics *n* (%)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Englesbe 20101** | | **John 20132** | | **Maruyama 20133** | |
|  | **No PVT (*n*=3147)** | **PVT (*n*=148)** | **No PVT (*n*=220)** | **PVT (*n*=70)** | **No PVT (*n*=108)** | **PVT (*n*=42)** |
| Sex (M/F) | 1905/1242 | 91/57 | 144/76 | 42/28 | 63/45 | 22/20 |
| Race | | | | | | |
| Black | 218 (6.9) | 7 (4.7) | - | - | - | - |
| White | - | - | 184 (83.6) | 60  (85.7) | - | - |
| Other | 2545 (80.9)  “Nonblack” | 131 (88.5)  “Nonblack” | - | - | - | - |
| Etiology | | | | | | |
| AIH | 95 (3) | 8 (5.4) | - | - | - | - |
| Biliary/cholestatic | 173 (5.4) | 7 (5.4) | 24 (11) | 5 (7.1) | - | - |
| Alcohol | 672 (21.4) | 31 (20.9) | 37 (16.9) | 5 (7.1) | - | - |
| Viral | 1253 (39.8) | 50 (34.1) | 62 (28.3) | 16 (27.1) | 108 | 42 |
| Cryptogenic/NASH | 72 (2.3) | 0 | 35 (16) | 12 (17.1) | - | - |
| Other | 449 (14.3) | 22 (14.9) | 37 (16.9) | 20 (28.6) | - | - |
| Age (yr) | 51.5 +/- 11.2 | 50.9 +/-10.8 | 55.8 +/-9.1 | 58.4 +/- 8.8 | 63.3 +/-8.68 | 62.4 +/- 11 |
| MELD | 12.1 +/- 7.2 | 13.3 +/-8.3 | 13.8 +/-4.5 | 14.9 +/- 5.9 | 10.2 | 10.6 |

1Presence of PVT at time of initial transplant evaluation or during the pre-transplant period; 2PVT category includes patients with PVT at baseline (*n*=47) and those that developed new PVT during the study period (*n*=23); 3Study only assessed patients with viral hepatitis. No data reported for race. PVT: Portal vein thrombosis; MELD: Model for end stage liver disease. NASH: Non-alcoholic steatohepatitis.